MAPT and Alzheimer disease: Several studies have shown a poor association of flortaucipir binding with non-AD tauopathies that have preferential accumulation of either 3R or 4R tau [52, 73, 74] although some studies have shown moderate tracer binding in brain tissues from patients with Pick’s disease and FTDP-17 [75].